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Aim: To evaluate the efficacy and safety of ipragliflozin vs placebo as add-on therapy to metfor-
min and sitagliptin in Korean patients with type 2 diabetes mellitus (T2DM).
Methods: This double-blind, placebo-controlled, multi-centre, phase III study was conducted in
Korea in 2015 to 2017. Patients were randomized to receive either ipragliflozin 50 mg/day or
placebo once daily for 24 weeks in addition to metformin and sitagliptin. The primary endpoint
was the change in glycated haemoglobin (HbA1c) from baseline to end of treatment (EOT).
Results: In total, 143 patients were randomized and 139 were included in efficacy analyses
(ipragliflozin: 73, placebo: 66). Baseline mean (SD) HbA1c levels were 7.90 (0.69)% for ipragliflo-
zin add-on and 7.92 (0.79)% for placebo. The corresponding mean (SD) changes from baseline
to EOT were −0.79 (0.59)% and 0.03 (0.84)%, respectively, in favour of ipragliflozin (adjusted
mean difference −0.83% [95% CI −1.07 to −0.59]; P < .0001). More ipragliflozin-treated
patients than placebo-treated patients achieved HbA1c target levels of <7.0% (44.4% vs 12.1%)
and < 6.5% (12.5% vs 1.5%) at EOT (P < .05 for both). Fasting plasma glucose, fasting serum
insulin, body weight and homeostatic model assessment of insulin resistance decreased signifi-
cantly at EOT, in favour of ipragliflozin (adjusted mean difference −1.64 mmol/L, −1.50 μU/mL,
−1.72 kg, and −0.99, respectively; P < .05 for all). Adverse event rates were similar between
groups (ipragliflozin: 51.4%; placebo: 50.0%). No previously unreported safety concerns were
noted.
Conclusions: Ipragliflozin as add-on to metformin and sitagliptin significantly improved glycae-
mic variables and demonstrated a good safety profile in Korean patients with inadequately con-
trolled T2DM.
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1 | INTRODUCTION
Diabetes presents a considerable burden to patients, their families,
and public health systems worldwide. In 2015, the International
Diabetes Federation (IDF) estimated there were 415 million cases of
diabetes and an additional 318 million adults with impaired glucose
tolerance worldwide.1 In Korea, it was estimated that ~4.8 million
people aged ≥30 years had type 2 diabetes mellitus (T2DM) in 2014,2
almost doubling the observed incidence in 2013.3
In line with the IDF guidelines, the Korean Diabetes Association
guidelines recommend managing T2DM with an initial therapy of met-
formin, in conjunction with lifestyle modification.4,5 Dual therapy may
be considered if patients' initial glycated haemoglobin (HbA1c) level is
≥7.5% or if the HbA1c target is not achieved within 3 months of initi-
ating metformin monotherapy.4,5 If inadequate glycaemic control per-
sists with dual therapy, a third agent with a complementary action
may be added.5 Because increased insulin resistance and diminishing
β-cell function tend to occur with T2DM progression, antidiabetic
agents that target components of the glucose metabolism pathway
may become less effective over time.6 Agents that work via alterna-
tive biological processes will ultimately be essential for chronic disease
management. Sodium-glucose co-transporter-2 (SGLT2) inhibitors act
via the kidney to inhibit SGLT2, and thereby suppress renal glucose
uptake, resulting in urinary glucose excretion.7 The unique mechanism
of SGLT2 inhibitors complements the actions of other antidiabetic
agents to reduce hyperglycaemia, making them suitable for use as part
of combination regimens in patients with T2DM, regardless of the
degree of insulin resistance and β-cell dysfunction.8
There is considerable interest in the combined use of SGLT2
inhibitors with dipeptidyl peptidase-4 (DPP-4) inhibitors for effective
glycaemic control without an increased potential for hypoglycaemia,
weight gain or cardiovascular diseases.8,9 Randomized studies have
demonstrated the efficacy and safety of triple therapy using a SGLT2
inhibitor, a DPP-4 inhibitor, and metformin in patients who have inad-
equately controlled T2DM.10,11 Ipragliflozin has been shown to be
efficacious and well tolerated both as a monotherapy12,13 and in dual
therapy with metformin or DPP-4 inhibitors14–18; however, no study
has investigated the effects of ipragliflozin added to metformin and a
DPP-4 inhibitor. In the present paper, we report the findings from a
phase III, randomized, placebo-controlled study, which compared the
efficacy and safety of ipragliflozin against placebo as an add-on ther-
apy to metformin and sitagliptin in Korean patients with inadequately
controlled T2DM.
2 | METHODS
2.1 | Study design
This was a double-blind, randomized, parallel-group, placebo-con-
trolled, multi-centre, phase III study conducted at 22 sites in Korea
between 2015 and 2017 (ClinicalTrials.gov identifier: NCT02452632).
The study comprised a 2-week single-blind placebo run-in period, fol-
lowed by a 24-week double-blind treatment period, and a 4-week
follow-up period. The study protocol and other relevant study docu-
ments were reviewed and approved by the institutional review board
at each study site. The study was conducted in compliance with the
principles of the Declaration of Helsinki, the International Conference
on Harmonization Harmonized Tripartite Guideline for Good Clinical
Practice, and the applicable local laws and regulations. All patients
provided written informed consent prior to study enrolment.
2.2 | Study population
Inclusion criteria included: age 19 to 74 years (inclusive); confirmed
T2DM diagnosis; stable diet and exercise programme ≥8 weeks prior to
study participation; treatment with metformin at ≥1500 mg/day
(or ≥1000 mg/day at the investigator's discretion) and sitagliptin at
100 mg/day for at least 8 weeks prior to study participation; HbA1c
7.0% to 10.5% (inclusive); and body mass index (BMI) 20.0 to 45.0 kg/m2
(inclusive). Key exclusion criteria included: diagnosis of type 1 diabetes
mellitus; proliferative diabetic retinopathy; renal disease, such as renovas-
cular occlusive disease, nephrectomy, or renal transplant; and pregnancy
or breastfeeding. Women of childbearing potential who were unwilling to
use appropriate contraception during the study were also excluded.
2.3 | Treatments
Eligible patients were randomly assigned to receive ipragliflozin
(50 mg/day) or placebo as an add-on therapy to metformin and sita-
gliptin. Randomization was stratified by study site and HbA1c level
(≥8.0% or <8.0%) using a computer-generated randomization sched-
ule. Assignment of study medications was blinded to all patients,
investigators and the sponsor. To maintain blinding, the packaging and
appearance of medications used in this study were identical and no
urinary glucose measurements were permitted during the study,
unless deemed necessary for safety reasons.
Patients whose fasting plasma glucose (FPG) levels were >14.99
mmol/L between weeks 0 and 4, >13.32 mmol/L between weeks 4 and
12, or >11.10 mmol/L between weeks 12 and 24, or whose HbA1c
levels were >8.0% between weeks 12 and 24, received rescue therapy
with glimepiride at the investigator's discretion. Apart from ipragliflozin,
sitagliptin, metformin and rescue medication, other medications that
may have an influence on blood glucose levels were prohibited during
the study. The use of weight-reducing medications and continuous sys-
temic administration of corticosteroids or immunosuppressants was
also prohibited.
2.4 | Study endpoints
The primary efficacy endpoint was the change in HbA1c from baseline
to end of treatment (EOT). Secondary efficacy endpoints included
changes in FPG, body weight, fasting serum insulin (FSI), and waist
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circumference from baseline to EOT, and the percentage of patients
achieving the HbA1c targets (<6.5% and <7.0%) at EOT. Exploratory
endpoints were changes in homeostatic model assessment of insulin
resistance (HOMA-IR) and β-cell function (HOMA-β) from baseline to
EOT. Key safety endpoints included the incidence of treatment-
emergent adverse events (TEAEs) and TEAEs leading to discontinua-
tion and changes in vital signs and clinical laboratory variables from
baseline to EOT. TEAEs were defined as adverse events (AEs) that
were observed after the first administration of the study medication
for the treatment period.
2.5 | Statistical analyses
The sample size was calculated based on results from three previous
studies: (1) dapagliflozin add-on to sitagliptin and metformin19; (2) dapa-
gliflozin add-on to metformin20; and (3) ipragliflozin add-on to metfor-
min.15 Assuming the difference for changes in HbA1c from baseline to
EOT between the ipragliflozin and placebo groups would be −0.45%
with an SD of 0.80, approximately 67 patients per treatment group
would be required to detect superiority of ipragliflozin to placebo with
90% power and a significance level of 5% for a two-sided test. Assum-
ing 5% of patients do not meet the criteria for the full analysis set
(FAS), ~140 randomized patients would be required for this study.
The FAS consisted of randomized patients who received at least
one dose of the study medication, and had at least one post-baseline
measurement. The per-protocol set (PPS) was a subgroup of the FAS
and consisted of eligible patients who received the study medication
for the entire treatment period, received metformin and sitagliptin for
≥56 days, had a compliance rate with the study medication of ≥80%,
did not use prohibited concomitant medications, and did not have any
clinically significant protocol deviations. The safety analysis set (SAF)
consisted of all patients who received at least one dose of the study
medication during the treatment period.
Efficacy analyses were performed on the FAS population. Sensi-
tivity analyses for HbA1c and FPG were repeated on the PPS popu-
lation. Safety analyses were performed on the SAF. The mean
differences in efficacy endpoints between the ipragliflozin and
FIGURE 1 Patient disposition during the study period. †In combination with metformin ≥1500 mg/day (or ≥1000 mg/day at physician's
discretion) and sitagliptin 100 mg/day. FAS, full analysis set; PPS, per protocol set; SAF, safety analysis set. ‡No urinary glucose measurements
were permitted during the study
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placebo groups were calculated using analysis of covariance
(ANCOVA), with the respective baseline value as a covariate and
treatment group as a fixed effect. Demographics, baseline character-
istics and safety endpoints were summarized according to treatment
group using descriptive statistics. Missing values at EOT were
imputed using the last observation carried forward method. Efficacy
data obtained after initiation of rescue therapy were excluded from
the analysis. HOMA-IR and HOMA-β were calculated using the fol-
lowing formulas: HOMA-IR = [FSI (μU/mL) × FPG (mg/dL)]/405;
HOMA-β = [360 × FSI (μU/mL)]/[FPG (mg/dL) − 63]. SAS Version
9.3 (SAS Institute Inc., Cary, North Carolina) was used for all statis-
tical analyses and a P value <.05 was taken to indicate statistical
significance.
3 | RESULTS
3.1 | Patient demographics and baseline
characteristics
A total of 237 patients entered the study. Of these, 143 patients were
randomized to receive ipragliflozin (n = 74) or placebo (n = 69). After
randomization, 30 patients discontinued from the study and
113 patients (ipragliflozin: 56; placebo: 57) completed the 24-week
treatment. The flow of patients through the study and reasons for dis-
continuation are summarized in Figure 1. The most commonly
reported reason for discontinuation in the ipragliflozin group was uri-
nary glucose measurements (n = 9), whereas worsening of disease
(n = 4) and consent withdrawal (n = 3) were the most common rea-
sons in the placebo group. There were 142 patients (ipragliflozin: 74;
placebo: 68) in the SAF, 139 patients (ipragliflozin: 73; placebo: 66) in
the FAS, and 109 patients (ipragliflozin: 54; placebo: 55) in the PPS.
Patient demographics and baseline characteristics were consis-
tent across treatment groups (Table 1). The mean (SD) duration of
exposure to the study medication was 146.58 (47.27) and 153.12
(42.21) days in the ipragliflozin and placebo groups, respectively. The
mean (SD) compliance rates with the study medications were 96.89
(3.72)% and 96.84 (8.62)% in the ipragliflozin and placebo groups,
respectively. One patient (1.4%) and 17 patients (25.8%) in the ipragli-
flozin and placebo groups, respectively, received rescue therapy with
glimepiride during the treatment period.
3.2 | Efficacy
3.2.1 | Primary efficacy outcome
Figure 2A shows the change in mean HbA1c levels during treatment
in both groups. HbA1c decreased significantly from baseline to the
EOT in the ipragliflozin group compared with the placebo group. The
mean (SD) HbA1c levels at baseline were 7.90 (0.69)% in the ipragli-
flozin group and 7.92 (0.79)% in the placebo group. The corresponding
mean (SD) changes in HbA1c levels from baseline to EOT were
−0.79% (0.59) and 0.03% (0.84), respectively, with an adjusted mean
difference of −0.83% (95% CI −1.07, −0.59; P < .0001). In the sub-
group analyses by gender, age, baseline HbA1c, and eGFR, HbA1c
reductions from baseline to EOT remained significantly greater with
ipragliflozin than placebo (Table S1). Significantly more patients in the
ipragliflozin group had HbA1c <7.0% at EOT compared with placebo
(44.4%; 32/72 vs 12.1%; 8/66; P < .0001). Similarly, a significantly
higher proportion of patients in the ipragliflozin group had HbA1c
<6.5% at EOT than the placebo group (12.5%; 9/72 vs 1.5%; 1/66;
P = .0183). The results for HbA1c in the PPS population were similar
to those in the FAS population (data not presented).
3.2.2 | Secondary efficacy outcomes
Figure 2B shows the change in mean FPG levels during treatment in
both groups. FPG decreased significantly from baseline to EOT in the
ipragliflozin group compared with placebo. The corresponding mean
(SD) changes were −1.20 (1.76) mmol/L and 0.42 (1.78) mmol/L,
respectively, with an adjusted mean difference of −1.64 mmol/L (95%
CI −2.18, −1.10; P < .0001). The results for FPG in the PPS population
were similar to those in the FAS population (data not presented).
Body weight decreased significantly from baseline to EOT in the
ipragliflozin group compared with placebo. The corresponding mean
(SD) changes were −1.96 (1.94) kg and −0.23 (1.69) kg, respectively,
with an adjusted mean difference of −1.72 kg (95% CI −2.34, −1.10;
P < .0001). More patients in the ipragliflozin group had a body weight
reduction of ≥5% at EOT than in the placebo group (19.7%; 14/71 vs
4.6%; 3/66). Similarly, waist circumference decreased significantly
from baseline to EOT in the ipragliflozin group compared with pla-
cebo. The corresponding mean (SD) changes were −1.93 (3.26) cm
TABLE 1 Patient demographics and baseline characteristics (full
analysis set)
Ipragliflozin
(n = 73)
Placebo
(n = 66)
Gender
Men 37 (50.7) 32 (48.5)
Women 36 (49.3) 34 (51.5)
Age, years 57.62 (8.26) 57.44 (7.88)
BMI, kg/m2 25.50 (3.07) 26.05 (3.79)
BMI ≥25 kg/m2 38 (52.1) 37 (56.1)
Body weight, kg 67.50 (12.50) 67.90 (10.98)
Waist circumference, cm 88.74 (8.10) 89.83 (9.08)
Duration of T2DM, months 139.41 (70.73) 135.98 (79.55)
Treatment with antidiabetic
agents other than metformin
and sitagliptin ≤12 weeks
prior to placebo run-in
17 (23.3) 12 (18.2)
HbA1c, % 7.90 (0.69) 7.92 (0.79)
FPG, mmol/L 8.77 (1.64) 8.85 (1.84)
FSI, μU/mL 7.82 (4.96) 8.49 (5.50)
eGFR at start of treatment,
mL/min/1.73 m2
89.38 (13.61) 90.66 (17.47)
eGFR at start of
treatment <90 mL/
min/1.73 m2
32 (45.1) 34 (51.5)
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtra-
tion rate; FSI, fasting serum insulin; FPG, fasting plasma glucose; HbA1c,
glycated haemoglobin; T2DM, type 2 diabetes mellitus. Data are presented
as n (%) or mean (SD). Percentages were calculated based on the number
of patients with available data.
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and −0.64 (3.80) cm, respectively, with an adjusted mean difference
of −1.44 cm (95% CI −2.78, −0.10; P = .0354).
In the ipragliflozin group FSI decreased significantly from baseline
to EOT compared with the placebo group. The corresponding mean
(SD) changes were − 1.14 (4.62) μU/mL and 0.08 (4.18) μU/mL,
respectively, with an adjusted mean difference of −1.50 μU/mL (95%
CI −2.93, −0.07; P = .0404). HOMA-IR decreased significantly from
baseline to EOT in the ipragliflozin group compared with placebo. The
corresponding mean (SD) changes were −0.63 (2.28) and 0.30 (1.95),
respectively, with an adjusted mean difference of −0.99 (95% CI
−1.73, −0.25; P = .0092). HOMA-β tended to increase from baseline
to EOT in the ipragliflozin group (mean [SD] change 0.46 [31.48])
compared with placebo (mean [SD] change −2.54 [20.54]); however,
the adjusted mean difference between groups was not statistically sig-
nificant (1.47 [95% CI −6.03, 8.98]; P = .6981).
3.3 | Safety
A summary of TEAEs is provided in Table 2. The incidence of TEAEs
and drug-related TEAEs was similar across groups. The majority of the
TEAEs were mild or moderate in severity. No deaths were reported in
this study. The incidence of TEAEs leading to permanent discontinua-
tion was low in both groups (6.8% in the ipragliflozin group and 2.9%
in the placebo group). The most common TEAEs were nasopharyngitis
and urticaria (4.1% each) in the ipragliflozin group and nasopharyngitis
(7.4%) in the placebo group. There were no reports of hypoglycaemia,
genital infection, volume depletion, and ketoacidosis in the ipragliflo-
zin group. Incidences of urinary tract infection and polyuria/pollakiuria
were low in both groups (ipragliflozin: 2.7% and 1.4%, respectively vs
placebo: 1.5% for both). Table 3 shows the changes in clinical and lab-
oratory variables from baseline to EOT in both groups. No clinically
significant changes in renal function, haematology, and fluid and elec-
trolyte balance variables were observed in either group. There was a
trend towards slight improvements in blood pressure (BP) [systolic BP
(SBP) −2.35 (10.47) mm Hg; diastolic BP (DBP) −1.49 (6.28) mm Hg],
triglyceride (TG) levels [−33.21 (134.85) mg/dL], and HDL cholesterol
levels [3.53 (8.04) mg/dL] at the EOT in the ipragliflozin group com-
pared with the placebo group [SBP −1.14 (9.76) mm Hg; DBP −0.17
(5.53) mm Hg; TG levels 8.94 (85.65) mg/dL; HDL cholesterol 0.36
(5.90) mg/dL].
4 | DISCUSSION
In this study of Korean patients with T2DM inadequately controlled
by metformin and sitagliptin, the addition of ipragliflozin significantly
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FIGURE 2 Time courses of A, glycated haemoglobin (HbA1c), and B, fasting plasma glucose (FPG) measurements. †Analysis of covariance
(ANCOVA) including baseline value as a covariate, and treatment group as fixed effect
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improved glycaemic variables after 24 weeks of treatment, compared
with placebo. Improvements in body weight and insulin resistance and
potential benefits on β-cell function and BP, TG levels, and HDL levels
were also observed with ipragliflozin add-on therapy. Ipragliflozin
add-on to dual therapy demonstrated a good safety and tolerability
profile, with no previously unreported safety concerns observed.
We demonstrate that triple therapy with ipragliflozin add-on to
metformin and sitagliptin significantly reduced HbA1c, FPG and body
weight from baseline in patients with inadequately controlled T2DM
(mean baseline HbA1c 7.90%). Significantly more patients reached
HbA1c target at EOT with the addition of ipragliflozin compared with
added placebo. Our results are in line with the results of recent ran-
domized studies that examined the effects of SGLT2 inhibitors as
add-on to metformin and a DPP-4 inhibitor. These studies demon-
strated favourable decreases in glycaemic variables and body weight
following the addition of an SGLT2 inhibitor.10,11 In a randomized
phase III study of patients with T2DM whose condition was inade-
quately controlled by metformin plus saxagliptin, addition of
10 mg/day dapagliflozin significantly reduced HbA1c levels, FPG
levels, and body weight compared with placebo. Dapagliflozin add-on
also led to significantly more patients achieving HbA1c target than
placebo.10 Similarly, in another randomized phase III study of patients
TABLE 2 Overall summary of treatment-emergent adverse events
(TEAEs) and selected TEAEs of interest (safety analysis set)
Ipragliflozin
(n = 74)
n (%)
Placebo
(n = 68)
n (%)
TEAEs 38 (51.4) 34 (50.0)
TEAEs by severity
Mild 27 (36.5) 23 (33.8)
Moderate 10 (13.5) 8 (11.8)
Severe 1 (1.4) 3 (4.4)
Serious TEAEs 7 (9.5) 4 (5.9)
Drug-related TEAEs 9 (12.2) 9 (13.2)
TEAEs leading to permanent
discontinuation
5 (6.8) 2 (2.9)
Drug-related TEAEs leading to permanent
discontinuation
4 (5.4) 1 (1.5)
TEAEs in ≥3.0% of patients in either treatment group
Nasopharyngitis 3 (4.1) 5 (7.4)
Urticaria 3 (4.1) 2 (2.9)
Gastritis 1 (1.4) 3 (4.4)
ALT increaseda 0 (0.0) 3 (4.4)
AST increaseda 0 (0.0) 3 (4.4)
TEAEs of special interest
Hypoglycaemia 0 (0.0) 1 (1.5)
Genital infection 0 (0.0) 0 (0.0)
Volume depletion-related event 0 (0.0) 0 (0.0)
Effects of ketoacidosis/increased ketone
bodies
0 (0.0) 0 (0.0)
Polyuria/pollakiuria 1 (1.4) 1 (1.5)
Urinary tract infections 2 (2.7) 1 (1.5)
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase;
SAF, safety analysis set
a Based on the investigator's judgment.
TABLE 3 Vital signs, clinical and laboratory parameters (safety
analysis set)
Ipragliflozin
(n = 74)
Placebo
(n = 68)
Systolic blood pressure,
mm Hg
−2.35 (10.47) −1.14 (9.76)
Diastolic blood pressure,
mm Hg
−1.49 (6.28) −0.17 (5.53)
Pulse rate, min 1.33 (8.55) 0.82 (6.92)
Total cholesterol, mg/dL 4.06 (23.15) 5.47 (20.20)
HDL cholesterol, mg/dL 3.53 (8.04) 0.36 (5.90)
LDL cholesterol, mg/dL 4.63 (20.09) 5.09 (17.77)
TG, mg/dL −33.21 (134.85) 8.94 (85.65)
Haematology
RBC × 106/μL 0.27 (0.30) 0.05 (0.24)
Haemoglobin, g/dL 0.69 (0.81) 0.11 (0.62)
Haematocrit, % 2.39 (2.59) 0.40 (2.32)
Renal function
BUN, mg/dL 1.86 (4.44) 0.18 (3.60)
Serum creatinine, mg/dL 0.00 (0.08) −0.00 (0.08)
BUN/ creatinine ratio 2.39 (5.85) 0.53 (4.93)
eGFR, mL/min/1.73 m2 −0.17 (10.54) 0.98 (10.76)
Liver function
AST, U/L −1.83 (10.42) 1.80 (11.38)
ALT, U/L −3.37 (12.30) 0.50 (14.92)
LDH, U/L 6.40 (56.80) −3.62 (56.56)
ALP, U/L 0.37 (12.59) −2.56 (9.16)
γ-GTP, U/L −10.69 (24.82) 2.00 (22.99)
Total bilirubin, mg/dL 0.02 (0.24) −0.03 (0.16)
Direct bilirubin, mg/dL −0.00 (0.11) −0.03 (0.11)
Fluid and electrolyte
balance
Na, mmol/L −0.29 (2.81) −0.62 (2.93)
K, mmol/L 0.04 (0.41) −0.04 (0.44)
Cl, mmol/L 0.36 (2.97) −0.15 (2.32)
Ca, mg/dL 0.04 (0.48) −0.12 (0.39)
Mg, mg/dL 0.15 (0.21) 0.02 (0.12)
P, mg/dL 0.19 (0.52) 0.03 (0.55)
Urine pH −0.24 (1.06) −0.02 (0.94)
Urine osmotic pressure,
mOsm/kgH2O
101.30 (194.77) 4.64 (186.16)
Urine Na/creatinine
ratio, mEq/g creatinine
−423.46 (6241.41) 922.60 (6180.34)
Urine K/creatinine
ratio, mEq/g creatinine
391.22 (3290.36) 36.23 (2014.26)
Urine cl/creatinine
ratio, mEq/g creatinine
−866.53 (7163.10) 1116.68 (6683.04)
Urine ca/creatinine
ratio, mg/g creatinine
1620.40 (6737.78) 926.30 (6567.32)
Urine mg/creatinine
ratio, mg/g creatinine
1776.00 (2187.29) 573.20 (2608.45)
Urine P/creatinine
ratio, mg/g creatinine
14 339.22 (22 106.34) 608.92 (17 746.19)
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST,
aspartate transaminase; BUN, blood urea nitrogen; Cre, creatinine; eGFR,
estimated glomerular filtration rate; γ-GTP, γ-glutamyl transpeptidase;
HDL, high density lipoprotein; LDH, lactate dehydrogenase; LDL, low den-
sity lipoprotein; RBC, red blood cells; TG, triglycerides. Mean (SD) changes
from baseline to end of treatment.
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inadequately controlled by metformin and linagliptin, addition of
10 mg/day empagliflozin significantly reduced HbA1c, FPG and body
weight compared with placebo at the end of the 24-week treat-
ment.11 These findings provide evidence for the benefits of using
SGLT2 inhibitors as an add-on in triple oral therapy to improve glycae-
mic control in patients inadequately controlled by metformin and
DPP-4 inhibitors, with the added advantage of body weight reduction.
In the present study, we observed significant reduction in insulin
resistance (HOMA-IR) and a trend towards improved β-cell function
(HOMA-β) with ipragliflozin add-on therapy compared with placebo
after 24 weeks of treatment. Previous studies of ipragliflozin monother-
apy and ipragliflozin add-on to metformin have shown improvements in
insulin resistance and β-cell function at the EOT.14,21 In a study in which
patients were treated with ipragliflozin monotherapy, significant reduc-
tions in HOMA-IR levels and significant increases in HOMA-β levels
from baseline were observed at the end of the 12-week treatment.21 In
another study in patients whose T2DM was inadequately controlled by
metformin, addition of ipragliflozin resulted in significant decrease in
HOMA-IR levels compared with placebo after 24 weeks of treatment.14
Other studies of SGLT2 inhibitors also reported a significant decrease in
insulin resistance and a significant increase in β-cell function at the
EOT.22,23 Taken together, these findings suggest that the glucose-
lowering effects of ipragliflozin, as for other SGLT2 inhibitors, can indi-
rectly improve insulin sensitivity and β-cell function. Considering that
insulin sensitivity and β-cell function tend to deteriorate as diabetes
progresses, SGLT2 inhibitors may provide a valuable treatment option,
especially in patients with longstanding T2DM.
Previous randomized studies of SGLT2 inhibitors as add-on to
metformin and DPP-4 inhibitors have demonstrated improvements in
BP after treatment.10,11 Recent studies of ipragliflozin add-on to met-
formin have demonstrated favourable changes in BP, TG levels, and
HDL levels at EOT.15,16 Consistent with the findings of these studies,
the present study showed slight improvements in BP, and TG and
HDL levels with the addition of ipragliflozin. These findings demon-
strate the potential of ipragliflozin to improve BP and lipid variables in
addition to glycaemic variables in patients with T2DM.
The addition of SGLT2 inhibitors to dual oral therapy has been
reported to be well tolerated in patients with inadequate glycaemic
control after treatment with metformin and DPP-4 inhibitors.10,11 The
overall incidence of AEs and the incidence of discontinuations
because of AEs were similar between the SGLT2 inhibitor add-on
group and the placebo group. Hypoglycaemia was infrequent in both
groups.10,11 In line with the results of these randomized studies, the
present study showed that the addition of ipragliflozin to metformin
and sitagliptin was well tolerated, with no previously unreported
safety concerns identified and no increased risk of hypoglycaemia
compared with placebo. Recent evidence suggested the potential risk
of developing diabetic ketoacidosis with SGLT2 inhibitors;24,25
however, no incidence of ketoacidosis was observed in our study.
A limitation of the present study was the relatively short study
duration, which precluded assessment of the longer-term efficacy and
safety of ipragliflozin add-on therapy in this population. The sample
size used in our study was also relatively small. Although triple therapy
with an SGLT2 inhibitor added on to metformin plus a DPP-4 inhibitor
has been reported in previous studies, this is nevertheless the first
study to investigate the effects of ipragliflozin added to metformin
and a DPP-4 inhibitor, and it provides important insights into the addi-
tional beneficial effects of ipragliflozin as an add-on to metformin and
sitagliptin in Korean patients. Future research may focus on defining
the long-term outcomes and safety profile of ipragliflozin add-on ther-
apy in a broader patient population, alongside other SGLT2 inhibitors.
In conclusion, the addition of ipragliflozin to metformin and sita-
gliptin therapy in Korean patients with inadequately controlled T2DM
resulted in significant improvements in glycaemic control compared
with placebo. The improvement was associated with significant
decreases in body weight and insulin resistance, with no observed or
tolerability concerns compared with placebo. Ipragliflozin add-on ther-
apy represents a valuable treatment option for patients failing on dual
therapy with metformin and sitagliptin, particularly those who have
concerns about weight gain or hypoglycaemia.
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